ArticleEuropean journal of medical research2025
Predictive role of serum sST2 for heart failure in children with severe pneumonia.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporal dynamics of cardiac biomarkers in therapy‑related cardiotoxicity: a prospective cardio‑oncology cohort study.Cardio-oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the predictive value of soluble suppression of tumorigenesis-2 (sST2) for heart failure (HF) in children hospitalized with severe pneumonia.
methodsA total of 109 children with severe pneumonia who were admitted to our hospital between January 2022 and December 2023 were selected. They were divided into HF and non-HF groups based on whether they developed HF. Clinical characteristics and clinical outcome data of the two groups were analyzed using relative factors analysis and logistic regression analysis.
resultsThe HF and non-HF groups consisted of 35 and 74 patients, respectively. Significant differences were observed between the groups in terms of age [20.0 (11.0-38.0) vs. 60.0 (36.0-96.0) months, P < 0.001], body mass index (16.7 ± 2.0 vs. 18.3 ± 2.5 kg/m
conclusionElevated sST2 shows potential as an independent risk factor for HF in children with severe pneumonia, but further studies are needed before routine clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.